WithdrawnNCT05057689
Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room
Medication studyAges 2–6United StatesAnxiety
Understand this study
Who could participate?
Listed age limits: 2 years to 6 years.
- Listed locations
- Little RockSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: September 2025
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Nationwide Children's Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 2 Years to 6 Years
- Official registry ID
- NCT05057689
- Official title
Show the full official title
A Double-blinded, Randomized Trial Comparing the Safety & Efficacy of Intranasal Dexmedetomidine, Intranasal Fentanyl & Intranasal Midazolam in the Pediatric Emergency Room
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Nationwide Children's Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Intranasal Dexmedetomidine (4 mcg/kg), Intranasal Fentanyl (2 mcg/kg) and Intranasal Midazolam (5 mg/kg).
Who can participate?
Listed age limits: 2 years to 6 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
